Transcend Medical has raised $51 million through its Series B round of financing. The funding was led by Investor Growth Capital and will help Transcend expand its glaucoma treatment line.
The ophthalmic device company intends to use the funds to develop the U.S. pivotal study of the CyPass Micro-Stent. The company’s existing investors are Canaan Partners, Finistere Ventures, HLM Venture Partners, Kaiser Permanente Ventures and Technology Partners.
Click here for the release from Transcend Medical.